GlobeNewswire·Nov 9, 2026, 8:32 AM ET

NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues

NeOnc Technologies Holdings CEO Amir Heshmatpour purchased 70,000 shares for approximately $230,510 via an SEC Form 4 filing.
Transactions occurred on November 5 & 6, with 30,000 shares bought at ~$3.17 per share & 40,000 shares at ~$3.39 per share.
Heshmatpour's total beneficial ownership now stands at approximately 7.77 million shares, including affiliated entities.
This purchase continues a 2026 buying pattern where Heshmatpour & Thomas C. Chen acquired 160,016 shares for ~$629,000 in August & September.
NeOnc is advancing NEO100, an intranasal treatment for recurrent IDH1-mutant high-grade glioma, & NEO212 for central nervous system cancers.
August data showed NEO100 Phase 2a met its primary endpoint with 48.9% six-month progression-free survival versus a 20% benchmark (p=0.0047).
Updated NEO100 data & NEO212 Phase 1 findings are scheduled for presentation at the Society for Neuro-Oncology annual meeting on November 13.

Company: Investors Tape and NeOnc
Keywords: Nasdaq:NTHI, Investors Tape and NeOnc, $NTHI, Insider buying, cancer, oncology, FDA, UAE